Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DKO16W
|
|||
| Drug Name |
MLS-101
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Phase 2 | [1] | |
| Company |
Mineralys Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aldosterone synthase (CYP11B2) | Target Info | Inhibitor | [1] |
| BioCyc | Superpathway of steroid hormone biosynthesis | |||
| Mineralocorticoid biosynthesis | ||||
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Metabolic pathways | ||||
| Pathwhiz Pathway | Steroidogenesis | |||
| Reactome | Glucocorticoid biosynthesis | |||
| Endogenous sterols | ||||
| WikiPathways | Metapathway biotransformation | |||
| ACE Inhibitor Pathway | ||||
| Oxidation by Cytochrome P450 | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| Glucocorticoid & Mineralcorticoid Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05001945) A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Phase 2 Study to Evaluate the Safety, Efficacy, and Tolerability of MLS-101 in Subjects With Uncontrolled Hypertension. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.